Patents by Inventor Wenyu Zhu

Wenyu Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20210269434
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: January 8, 2021
    Publication date: September 2, 2021
    Inventors: Xiaozhao Wang, Wenyu Zhu, Jeffrey Yang, Alexander Sokolsky, Chunhong He, Zhenwu Li, Chao Qi, Yong Li, Pei Gan, Peter Carlsen, Gia Hoang, Heeoon Han, Chenyin Marshall Law, Fenglei Zhang, Padmaja Polam, Le Zhao, Liangxing Wu, Wenqing Yao
  • CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY
    Publication number: 20210230294
    Abstract: Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 29, 2021
    Inventors: Horacio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane, Hui Wang, Yingnan Chen, Xiaozhao Wang, Peter Niels Carlsen, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Wenyu Zhu, Taisheng Huang
  • SPIRO COMPOUNDS AS INHIBITORS OF KRAS
    Publication number: 20210230162
    Abstract: Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with KRAS activity such as cancer.
    Type: Application
    Filed: January 20, 2021
    Publication date: July 29, 2021
    Inventors: Le Zhao, Xiaozhao Wang, Wenyu Zhu, Haolin Yin, Liangxing Wu, Wenqing Yao
  • Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
    Publication number: 20210205311
    Abstract: The present application provides methods of treating cancer using a combination of an inhibitor of A2A and/or A2B and an inhibitor of PD-1 and/or PD-L1.
    Type: Application
    Filed: December 30, 2020
    Publication date: July 8, 2021
    Inventors: Hui Wang, Juan Carlos Almagro, Rebecca A. Buonpane, Peter Niels Carlsen, Taisheng Huang, Yong Li, Luping Lin, Horacio G. Nastri, Chao Qi, Shaun M. Stewart, Pramod Unnikrishnan Thekkat, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Jing Zhou, Wenyu Zhu
  • Heterocyclic compounds useful as Pim kinase inhibitors
    Patent number: 11053215
    Abstract: The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: July 6, 2021
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Yun-Long Li, Alexander Sokolsky, Anlai Wang, Wenyu Zhu, Jincong Zhuo
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20210107900
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: August 18, 2020
    Publication date: April 15, 2021
    Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
  • 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase
    Publication number: 20210030722
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Application
    Filed: April 15, 2020
    Publication date: February 4, 2021
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
  • IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE
    Publication number: 20200397893
    Abstract: Compositions and methods for inducing PD-L1 internalization are disclosed. The methods include reducing the amount of cell surface PD-L1 by contacting a cell expressing PD-L1 with a compound that binds to cell surface PD-L1 and induces PD-L1 internalization. Compounds that induce PD-L1 internalization can be used to enhance, stimulate and/or increase an immune response and treat a PD-1-related disease or condition.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 24, 2020
    Inventors: Phillip C. Liu, Alla Volgina, Richard Wynn, Nina Zolotarjova, Liangxing Wu, Kaijiong Xiao, Song Mei, Liang Lu, Wenyu Zhu, Yingda Ye, Haisheng Wang, Ding-Quan Qian, Wenqing Yao
  • Immunomodulator compounds and methods of use
    Patent number: 10806785
    Abstract: Compositions and methods for inducing PD-L1 internalization are disclosed. The methods include reducing the amount of cell surface PD-L1 by contacting a cell expressing PD-L1 with a compound that binds to cell surface PD-L1 and induces PD-L1 internalization. Compounds that induce PD-L1 internalization can be used to enhance, stimulate and/or increase an immune response and treat a PD-1-related disease or condition.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: October 20, 2020
    Assignee: Incyte Corporation
    Inventors: Liang Lu, Wenyu Zhu, Ding-Quan Qian, Kaijiong Xiao
  • 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
    Patent number: 10653677
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: May 19, 2020
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
  • TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS
    Publication number: 20200040002
    Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: June 27, 2019
    Publication date: February 6, 2020
    Inventors: Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
  • FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
    Publication number: 20200031835
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 30, 2020
    Inventors: Xiaozhao Wang, Peter Niels Carlsen, Pei Gan, Gia Hoang, Yong Li, Chao Qi, Liangxing Wu, Wenqing Yao, Zhiyong Yu, Wenyu Zhu
  • HETEROCYCLIC COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
    Publication number: 20200002309
    Abstract: The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.
    Type: Application
    Filed: September 9, 2019
    Publication date: January 2, 2020
    Inventors: Oleg Vechorkin, Yun-Long Li, Alexander Sokolsky, Anlai Wang, Wenyu Zhu, Jincong Zhuo
  • Heterocyclic compounds useful as Pim kinase inhibitors
    Patent number: 10450296
    Abstract: The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: October 22, 2019
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Yun-Long Li, Alexander Sokolsky, Anlai Wang, Wenyu Zhu, Jincong Zhuo
  • 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase
    Publication number: 20190298700
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Application
    Filed: June 19, 2019
    Publication date: October 3, 2019
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
  • 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
    Patent number: 10369137
    Abstract: The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: August 6, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu
  • Tricyclic fused thiophene derivatives as JAK inhibitors
    Patent number: 10370387
    Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: August 6, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yun-Long Li, Wenyu Zhu, Song Mei
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20190225601
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: April 2, 2019
    Publication date: July 25, 2019
    Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
  • HETEROCYCLYLAMINES AS PI3K INHIBITORS
    Publication number: 20190134040
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: August 24, 2018
    Publication date: May 9, 2019
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Wenyu Zhu, Joseph Glenn, Thomas P. Maduskuie, JR., Richard B. Sparks, Brent Douty, Chunhong He
  • CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINES DERIVATIVES AS JAK INHIBITORS
    Publication number: 20190135813
    Abstract: The present invention provides cyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines of Formula I: wherein X, Y, Z, L, A, R5, n and m are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Application
    Filed: July 27, 2018
    Publication date: May 9, 2019
    Inventors: James D. Rodgers, Stacey Shepard, Wenyu Zhu, Lixin Shao, Joseph Glenn